4/A: Turning Point Brands Executive Chairman David Glazek Amends SEC Filing to Correct Stock Unit Grant Date
SEC Form 4/A Filing
David Glazek, Executive Chairman of Turning Point Brands, files an amended SEC Form 4/A to correct the grant date of restricted stock units and report recent transactions involving common stock and derivative securities.
Summary
- David Glazek, Executive Chairman of Turning Point Brands, filed an amended SEC Form 4/A on March 7, 2025.
- The amendment corrects an administrative error in the original filing from March 5, 2025, regarding the grant date of restricted stock units.
- The corrected filing reports Glazek's receipt of 14,921 restricted stock units on March 5, 2025, under the company's 2021 Equity Incentive Plan.
- The filing also details several transactions on March 3, 2025, including the acquisition of common stock upon settlement of performance restricted stock units and shares withheld for tax payments.
- Glazek acquired 5,544 shares of common stock, 5,259 shares of common stock, and 4,411 shares of common stock at a price of $70.34.
- He also disposed of 1,275 shares and 2,027 shares of common stock at $70.34 for tax payments.
- As of March 5, 2025, Glazek beneficially owns 127,083 shares of common stock and 35,956 restricted stock units.
- He also holds options for 54,289 shares exercisable at $27.19 and 77,519 shares exercisable at $20.71.
- The options were granted under the Turning Point Brands, Inc. 2021 Equity Incentive Plan and vest quarterly.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing. The sentiment is neutral, reflecting standard executive compensation practices and transparency.
Positives
- The filing indicates that performance criteria for restricted stock units were met, leading to the issuance of shares to Glazek.
- Glazek's continued holdings in common stock and options suggest a vested interest in the company's success.
Negatives
- The need for an amendment indicates an initial administrative error in reporting the grant date of restricted stock units.
Risks
- Executive compensation and equity grants are subject to scrutiny and can impact shareholder sentiment if not perceived as aligned with company performance.
- Tax liabilities arising from vesting equity can lead to stock sales, potentially creating downward pressure on the stock price.
Industry Context
Executive compensation through equity grants is a common practice in publicly traded companies to align management's interests with those of shareholders. SEC filings provide transparency into these transactions.
Comparison to Industry Standards
- Equity grants are a standard component of executive compensation packages across various industries.
- Companies like Altria Group (MO) and British American Tobacco (BTI), which operate in similar sectors, also utilize equity-based compensation.
- The vesting schedules and exercise prices of options are generally benchmarked against industry peers to ensure competitiveness.
Stakeholder Impact
- Shareholders may be interested in the details of executive compensation and equity ownership.
- Employees may view equity grants as a positive incentive for management.
Key Dates
| Date | Description |
|---|---|
| 05/12/2023 | Date of grant for options exercisable at $20.71, vesting quarterly until 05/12/2033 |
| 03/11/2024 | Date of grant for options exercisable at $27.19, vesting quarterly until 03/11/2034 |
| 03/03/2025 | Date of transactions involving common stock acquisition and disposal for tax payments. |
| 03/05/2025 | Corrected date of restricted stock unit grant. |
| 03/05/2025 | Date of original Form 4 filing (amended). |
| 03/07/2025 | Date of amended Form 4/A filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.